In last trading session, Allogene Therapeutics Inc (NASDAQ:ALLO) saw 3.13 million shares changing hands with its beta currently measuring 0.33. Company’s recent per share price level of $1.2 trading at -$0.04 or -3.23% at ring of the bell on the day assigns it a market valuation of $262.48M. That closing price of ALLO’s stock is at a discount of -215.0% from its 52-week high price of $3.78 and is indicating a premium of 28.33% from its 52-week low price of $0.86. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.31 million shares which gives us an average trading volume of 3.07 million if we extend that period to 3-months.
For Allogene Therapeutics Inc (ALLO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.36. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Upright in the red during last session for losing -3.23%, in the last five days ALLO remained trading in the red while hitting it’s week-highest on Friday, 06/20/25 when the stock touched $1.2 price level, adding 9.72% to its value on the day. Allogene Therapeutics Inc’s shares saw a change of -54.02% in year-to-date performance and have moved -6.98% in past 5-day. Allogene Therapeutics Inc (NASDAQ:ALLO) showed a performance of 11.11% in past 30-days. Number of shares sold short was 26.04 million shares which calculate 7.91 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 33.5 to the stock, which implies a rise of 96.42% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 55. It follows that stock’s current price would drop -483.33% in reaching the projected high whereas dropping to the targeted low would mean a loss of -483.33% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.26% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 23.59% while estimates for its earnings growth in next 5 years are of 8.47%.
Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders
Insiders are in possession of 17.74% of company’s total shares while institution are holding 80.54 percent of that, with stock having share float percentage of 97.91%. Investors also watch the number of corporate investors in a company very closely, which is 80.54% institutions for Allogene Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at ALLO for having 31.26 million shares of worth $72.83 million. And as of 2024-06-30, it was holding 16.4491 of the company’s outstanding shares.
The second largest institutional holder is TPG GP A, LLC, which was holding about 18.72 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.8493 of outstanding shares, having a total worth of $43.61 million.
